UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study

Clinical infectious diseases, 2010-10, Vol.51 (7), p.855-864

2010

Volltextzugriff (PDF)

Changes in plasma lipidome following initiation of antiretroviral therapy

PloS one, 2018-08, Vol.13 (8), p.e0202944-e0202944

2018

Volltextzugriff (PDF)

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

Therapeutic drug monitoring, 2017-12, Vol.39 (6), p.654-658

2017

Volltextzugriff (PDF)

A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry

Therapeutic drug monitoring, 2015-04, Vol.37 (2), p.220-228

2015

Volltextzugriff (PDF)

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

Antimicrobial Agents and Chemotherapy, 2012-03, Vol.56 (3), p.1427-1433

2012

Volltextzugriff (PDF)

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART

PloS one, 2015-02, Vol.10 (2), p.e0118608

2015

Volltextzugriff (PDF)

Therapeutic vaccination against HIV: current progress and future possibilities

Clinical science (1979), 2006-01, Vol.110 (1), p.59-71

2006

Volltextzugriff (PDF)

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

AIDS (London), 2006-01, Vol.20 (2), p.294-297

2006

Volltextzugriff (PDF)

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

Neuroradiology, 2012-12, Vol.54 (12), p.1331-1339

2012

Volltextzugriff (PDF)

Cerebrospinal‐fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19541-n/a

2014

Volltextzugriff (PDF)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Clinical pharmacokinetics, 2016-07, Vol.55 (7), p.861-873

2016

Volltextzugriff (PDF)

Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults

Antiviral therapy, 2006-01, Vol.11 (2), p.179-186

2006

Volltextzugriff (PDF)

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

The Lancet (British edition), 2014-04, Vol.383 (9927), p.1474-1482

Anon

2014

Volltextzugriff (PDF)

Practical applications of the HIV lipodystrophy case definition

The AIDS reader, 2003-10, Vol.13 (10), p.480-487

2003

Volltextzugriff (PDF)

Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing cART? A Randomized, Controlled Study

Clinical infectious diseases, 2010-03, Vol.50 (6), p.920-929

2010

Volltextzugriff (PDF)

Assessing site performance in the Altair study, a multinational clinical trial

Trials, 2015-04, Vol.16 (1), p.138-138, Article 138

2015

Volltextzugriff (PDF)

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical infectious diseases, 2015-04, Vol.60 (7), p.1026-1032

2015

Volltextzugriff (PDF)

Comparison of central and local HIV-1 RNA quantification from two international clinical trials

AIDS (London), 2014-10, Vol.28 (16), p.2480-2483

2014

Volltextzugriff (PDF)

Interleukin 12-augmented T cell proliferation of peripheral blood mononuclear cells from HIV-seropositive individuals is associated with interleukin 12 receptor β2 upregulation

AIDS research and human retroviruses, 2003-04, Vol.19 (4), p.283-292

2003

Volltextzugriff (PDF)

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection

Human vaccines, 2010-10, Vol.6 (10), p.835-840

2010

Volltextzugriff (PDF)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

Journal of antimicrobial chemotherapy, 2011-03, Vol.66 (3), p.635-640

2011

Volltextzugriff (PDF)

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase 1/11a trial in Thai volunteers at low risk of HIV infection

Human vaccines, 2010-10, Vol.6 (10), p.835-840

2010

Volltextzugriff (PDF)

Neurocognition and HIV

HIV Australia, 2013-06, Vol.11 (2), p.36-38

Rebekah Puls

2013

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(27)
Bücher
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Science & Technology
(20)
Life Sciences & Biomedicine
(18)
Female
(13)
Male
(13)
Adult
(12)
Hiv
(12)
Infectious Diseases
(12)
Antiretroviral Drugs
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Hiv Infections - Drug Therapy
(9)
Human Immunodeficiency Virus
(9)
Anti-Hiv Agents - Administration & Dosage
(8)
Immunology
(8)
Anti-Hiv Agents - Therapeutic Use
(7)
Human Viral Diseases
(7)
Microbiology
(7)
Viral Diseases
(7)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study

Changes in plasma lipidome following initiation of antiretroviral therapy

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART

Therapeutic vaccination against HIV: current progress and future possibilities

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

Cerebrospinal‐fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

Practical applications of the HIV lipodystrophy case definition

Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing cART? A Randomized, Controlled Study

Assessing site performance in the Altair study, a multinational clinical trial

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Comparison of central and local HIV-1 RNA quantification from two international clinical trials

Interleukin 12-augmented T cell proliferation of peripheral blood mononuclear cells from HIV-seropositive individuals is associated with interleukin 12 receptor β2 upregulation

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase 1/11a trial in Thai volunteers at low risk of HIV infection

Neurocognition and HIV

536Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r)-based Anti-Retroviral Therapy (ART)

Suchergebnisse filtern